Find Clinical Drug Pipeline Developments & Deals for N-Acetylcysteine

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Auditus

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): N-Acetylcysteine,2,4-disulfonyl alpha-phenyl tertiary butyl nitrone

            Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Oblato

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 12, 2020

            Details:

            Oblato assumes exclusive rights to a drug known as NHPN-1010. Oblato is expected to initiate a phase 2 clinical trial to evaluate the potential of the drug to prevent and treat hearing loss.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): N-Acetylcysteine

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: ATAI Life Sciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership January 06, 2020

            Details:

            The partners will develop a short-term treatment which includes intranasal delivery of low doses of N-acetylcysteine for mild Traumatic Brain Injury (mTBI) or concussion.